Physician profile
Beth Schroeder
NPI 1184616013
$2,751.29
in general payments reported to CMS, 2019-2025
29 companies · $211 in 2025
The $211 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $221 · 2021: $413 · 2022: $525 · 2023: $581 · 2024: $519 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,310.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $524.00 | 2022-2025 | Qulipta, Vraylar |
| Pfizer INC. | $373.09 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $296.23 | 2019-2025 | Gardasil 9, Vaxelis, Capvaxive |
| Lilly USA, LLC | $223.51 | 2019-2023 | Emgality, Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.64 | 2019-2024 | Stiolto Respimat, Spiriva Respimat, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $192.46 | 2021-2023 | |
| Novo Nordisk INC | $138.79 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $79.54 | 2020-2022 | |
| Medtronic, INC. | $74.77 | 2023 | Minimed 780g |
| Novartis Pharmaceuticals Corporation | $72.47 | 2019-2022 | |
| Amgen INC. | $69.35 | 2020-2023 | Repatha, Otezla |
| Nestle Healthcare Nutrition INC. | $59.09 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $42.02 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $41.08 | 2024-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $40.55 | 2022-2025 | Ajovy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $38.03 | 2023-2024 | Veozah |
| Eisai INC. | $29.42 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $28.79 | 2020-2022 | |
| Dexcom, INC. | $28.48 | 2022-2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $24.59 | 2021-2022 | |
| Allergan, INC. | $22.94 | 2022 | |
| Exact Sciences Corporation | $22.39 | 2025 | The Cologuard Plus Collection Kit |
| Edwards Lifesciences Corporation | $21.02 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Neurocrine Biosciences, INC. | $18.88 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.22 | 2022 | |
| Corium, LLC | $16.02 | 2024 | Azstarys |
| Amarin Pharma, INC. | $15.77 | 2021 | |
| Vanda Pharmaceuticals INC. | $13.52 | 2024 | Fanapt |
| Glaxosmithkline, LLC. | $12.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Schroeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.